FindTrial
Sign In

GNC-038

DRUG7 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaNK/T Cell LymphomaNon Hodgkin LymphomaNon-Hodgkin LymphomaNon-hodgkin's LymphomaPrimary Central Nervous System LymphomaRheumatoid Arthritis

Phase 1

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Active, not recruitingNCT04606433
Sichuan Baili Pharmaceutical Co., Ltd.Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Start: 2020-11-04End: 2025-12-31Updated: 2025-09-26
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Active, not recruitingNCT05192486
Sichuan Baili Pharmaceutical Co., Ltd.Diffuse Large B-cell Lymphoma
Start: 2022-08-10End: 2025-12-31Updated: 2025-09-26
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Active, not recruitingNCT05485753
Sichuan Baili Pharmaceutical Co., Ltd.Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Start: 2023-02-10End: 2025-12-31Updated: 2025-09-26
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RecruitingNCT05623982
Sichuan Baili Pharmaceutical Co., Ltd.Non-hodgkin's Lymphoma
Start: 2022-09-26End: 2027-12-01Target: 40Updated: 2026-08-27
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Active, not recruitingNCT05627856
Sichuan Baili Pharmaceutical Co., Ltd.NK/T Cell Lymphoma, Non-Hodgkin Lymphoma, Vascular Immunomother T Cell Lymphoma
Start: 2023-02-21End: 2025-12-31Updated: 2025-09-26
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
RecruitingNCT06857227
Sichuan Baili Pharmaceutical Co., Ltd.Rheumatoid Arthritis
Start: 2025-03-17End: 2027-12-31Target: 54Updated: 2025-04-15
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
RecruitingNCT06857214
Sichuan Baili Pharmaceutical Co., Ltd.Systemic Lupus Erythematosus
Start: 2025-06-04End: 2027-12-01Target: 84Updated: 2026-07-10

Related Papers

GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
Journal of Clinical Oncology2023-06-017 citations
791 Multi-specific Guidance and Navigation Control (GNC) T cell engagers convert PDL1 adaptive resistance to drug sensitivity
Regular and Young Investigator Award Abstracts2021-11-011 citations